Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Total Liabilities (2016 - 2025)

Dare Bioscience's Total Liabilities history spans 11 years, with the latest figure at $29.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 5.4% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, up 5.4%, while the annual FY2025 figure was $29.6 million, 5.4% up from the prior year.
  • Total Liabilities reached $29.6 million in Q4 2025 per DARE's latest filing, up from $27.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $32.7 million in Q4 2022 to a low of $7.1 million in Q2 2021.
  • Average Total Liabilities over 5 years is $22.5 million, with a median of $24.7 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: skyrocketed 159.39% in 2022, then dropped 28.52% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $17.1 million in 2021, then skyrocketed by 91.84% to $32.7 million in 2022, then dropped by 19.52% to $26.3 million in 2023, then rose by 6.77% to $28.1 million in 2024, then grew by 5.4% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Total Liabilities are $29.6 million (Q4 2025), $27.9 million (Q3 2025), and $25.7 million (Q2 2025).